Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29642211
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
A case report of sofosbuvir and daclatasvirto treat a patient with acute
hepatitis C virus genotype 2 monoinfection
#MMPMID29642211
Li C
; Hu J
Medicine (Baltimore)
2018[Apr]; 97
(15
): e0416
PMID29642211
show ga
RATIONALE: Direct-acting antivirals (DAAs) are the first-line treatment for
patients with chronic hepatitis C virus (HCV) infection. However, its effects on
patients with acute HCV infection are poorly understood, and the data for
treatment of DAAs for genotype 2 acute monoinfection patients with HCV are
lacking. PATIENT CONCERNS: In this case report, a 26 year-old Chinese female
acquired a tattoo and developed fatigue, nausea, and anorexia. Laboratory tests
showed abnormal liver function. DIAGNOSES: Five months after the patient acquired
a tattoo, laboratory tests showed anti-HCV antibody titers were 26.0?s/co, HCV
RNA was 5.74×10?IU/mL, and HCV genotype was 2a. The patient was diagnosed with
acute hepatitis C (AHC). INTERVENTIONS: HCV RNA did not have spontaneous
clearance 12 weeks after the infection of the patient. The patient received
sofosbuvir (SOF) and daclatasvir (DCV) combination treatment for 12 weeks.
OUTCOMES: Laboratory tests showed HCV RNA was undetectable at weeks 4, and
anti-HCV antibody was in seroconversion at weeks 12 during treatment. The patient
achieved a sustained virological response 36 weeks after the end of treatment.
LESSONS: Patients with acute HCV genotype 2 monoinfection would benefit from
antiviral treatment with SOF and DCV.
free
free
free
